PCV30 Analysis of Generic Simvastatin and Atorvastatin Versus Branded Rosuvastatin in Hyperlipidemia Patients- A Budget Impact Model from a Managed Care Organization Perspective in the United States
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.633
https://www.valueinhealthjournal.com/article/S1098-3015(12)00698-5/fulltext
Title :
PCV30 Analysis of Generic Simvastatin and Atorvastatin Versus Branded Rosuvastatin in Hyperlipidemia Patients- A Budget Impact Model from a Managed Care Organization Perspective in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00698-5&doi=10.1016/j.jval.2012.03.633
First page :
A117
Section Title :
Cardiovascular Disorders
Open access? :
No
Section Order :
103